Is Legend Biotech Corp (LEGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.0% / 30% | 32.0% / 30% | 3.6% / 30% | 9.76% / 5% | ✗ NOT HALAL |
| DJIM | 10.0% / 33% | 32.0% / 33% | 3.6% / 33% | 9.76% / 5% | ✗ NOT HALAL |
| MSCI | 21.0% / 33% | 67.2% / 33% | 7.5% / 33% | 9.76% / 5% | ✗ NOT HALAL |
| S&P | 10.0% / 33% | 32.0% / 33% | 3.6% / 33% | 9.76% / 5% | ✗ NOT HALAL |
| FTSE | 21.0% / 33% | 67.2% / 33% | 7.5% / 50% | 9.76% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 20.0% | |
| Operating Margin | -6.7% | |
| Net Margin | -28.8% | |
| Return on Equity (ROE) | -29.1% | |
| Return on Assets (ROA) | -5.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$100M |
| Free Cash Flow | -$129M |
| Total Debt | $414M |
| Debt-to-Equity | 41.3 |
| Current Ratio | 2.0 |
| Total Assets | $1.7B |
Price & Trading
| Last Close | $17.49 |
| 50-Day MA | $18.52 |
| 200-Day MA | $28.90 |
| Avg Volume | 2.3M |
| Beta | 0.1 |
|
52-Week Range
$16.24
| |
About Legend Biotech Corp (LEGN)
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Legend Biotech Corp (LEGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Legend Biotech Corp is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Legend Biotech Corp's debt ratio?
Legend Biotech Corp's debt ratio is 10.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 21.0%.
What are Legend Biotech Corp's key financial metrics?
Legend Biotech Corp has a market capitalization of $3.1B, and revenue of $1.0B. The company maintains a gross margin of 20.0% and a net margin of -28.8%. Return on equity stands at -29.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.